AJANTPHARM — Ajanta Pharma Share News
0.000.00%
- IN₹410.29bn
- IN₹405.00bn
- IN₹54.53bn
Brief: India's Ajanta Pharma Dec Qtr Consol Profit Rises
Brief: India's Ajanta Pharma Sept-Quarter Profit Falls
India's Ajanta Pharma rises on Q1 profit
Brief: India's Ajanta Pharma June-Qtr Consol PAT Rises
Brief: India's Ajanta Pharma March-Qtr Consol Profit Falls
Brief: India's Ajanta Pharma Dec-Qtr Consol Profit More Than Halves
Brief: India's Ajanta Pharma Sept-Qtr Profit Falls
Brief: Ajanta Pharma Says NCLT Did Not Approve Proposed Scheme Of Co With Gabs Investments
Brief: India's Ajanta Pharma June Quarter Consol PAT Rises
Brief: Ajanta Pharma's Formulation Facility At Dahej Inspected By U.S. FDA
Brief: Ajanta Pharma Says There Is No Action Against Co From Office Of Drug Controller General Of India
Media: India's Ajanta Pharma under scanner for marketing unapproved drugs - Mint
Brief: Ajanta Pharma Gets Shareholders' Nod For Reappointment Of Yogesh M Agrawal As MD
Brief: India's Ajanta Pharma March Qtr Consol Profit Falls
Brief: Ajanta Pharma Says No Form 483 Issued By USFDA To Facility At Dahej
Brief: India's Ajanta Pharma Dec Qtr Consol Profit Rises
Brief: Ajanta Pharma's Vice-Chairman Purushottam B. Agrawal Resigns
Brief: India's Ajanta Pharma launches clonidine hydrochloride extended release tablets in U.S.
Brief: India's Ajanta Pharma Sept-qtr consol profit rises marginally